Clinical Trial Search

Primary: Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) — 32.67; 27.4; 33.67; 27.33 score on a scale

Primary: Tremor Amplitude — 127; 104; 150; 100 cm/s^2

Primary: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb) — -0.47; 0.07 degree — p=0.144

Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale

Primary: Tremor Model Accuracy — 24; 21 Normalized RMSE (%)

Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale

Primary: Regions With fMRI Differences Between ET and Controls — 139; 93; 85; 74 Number of Activated Voxels

Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216

Primary: Digital Spirography — 1.04; 1.00 millimeters of tremor amplitude

Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale

Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at the End of Maintenance — 5.20 Points on UPDRS scale

Primary: Tremor Power — 64 Percentage of tremor power reduction

Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants

Primary: Percent Change in Tremor Power — 43; 9 percent tremor improvement

Primary: Change in TETRAS Spiral Rating After Stimulation — 2.95; 2.63; 2.41; 2.23 score on a scale

Primary: Mean TRS (Tremor Rating Score) — 26.6; 27.6 units on a scale

Primary: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score — 39.41; 29.50; 23.60 units on a scale

Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345

Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer…

Primary: Change in the MDS-UPDRS Tremor Subscore — 0.25; 0.27 score on a scale — p=0.5

Primary: Tremor Motor Score - Clinical Rating Scale for Tremor (CRST Part A (Upper Extremity) + Part B) Percent Change From Baseline — 46.9; -0.1 Percent Change from Baseline…

Primary: Change From Baseline Compared to Placebo in TETRAS Performance Subscale Part 4 Upper Limb Tremor Score on Day 29 — -2.31; -1.24 score on a scale — p=0.0491

Primary: Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 12.0; 20.0; 0; 0 percentage of participants

Primary: Clinical Rating Scale for Tremor (CRST) — 18.39534884; 13.97674419; 14.58139535 score on a scale — p=<0.01

Primary: Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score — -6.4; -5.3 score on a scale — p==0.2363

Primary: Baseline and Day 28 on The Essential Tremor Rating Assessment Scale Performance Subscale (TETRAS-PS) Total Score — 22.7; 22.8; 21.1; 20.7 score on a scale

Primary: Part A: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7 — 4.36; -0.69 score on a scale

Primary: Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score — -1.427; -2.912 Scores on a scale — p=0.1048

Primary: Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale — 0; 8 participants — p=0.0007

Primary: Severity of Participants Reporting Study-related Adverse Events at Each Dose Level — 1; 1; 1; 1.25 units on a scale